The White House has released new information about the Precision Medicine Initiative, a research program to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies for individualized patient care.
Precision medicine has been instrumental in the development of drugs that target genetic abnormalities, such as ivacaftor (Kalydeco; Vertex) for the treatment of cystic fibrosis (CF) in patients ≥6yrs who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, or S549R. The Precision Medicine Initiative will include both public and private efforts for advancements in genomics, emerging methods for managing and analyzing large data sets while protecting patient privacy, and health information technology to accelerate biomedical discoveries.
The President’s 2016 budget will include a $215 million investment that includes the following efforts:
- $130 million to the National Institutes of Health (NIH) for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
- $70 million to the National Cancer Institute (NCI) to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
- $10 million to the Food and Drug Administration (FDA) to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
- $5 million to the Office of the National Coordinator for Health Information Technology (ONC) to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.
For more information visit WhiteHouse.gov.